此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

评估性腺功能减退男性接受 JATENZO® 治疗 12 个月后肾上腺功能的 4 期研究

2026年9月28日 更新者:Tolmar Inc.

一项 4 期开放标签研究,旨在评估接受 JATENZO® 治疗 12 个月的性腺功能减退男性的主要肾上腺功能(糖皮质激素轴)

TOL-CLAR-20024 is a Phase 4, multi-center, open-label safety study evaluating the potential effect of JATENZO on adrenal function in hypogonadal men treated with JATENZO for 12 months.

研究概览

地位

完全的

详细说明

Following all screening activities and confirmation that the subject has met all eligibility requirements, JATENZO treatment for approximately 1 year will begin. The dose of JATENZO will be titrated using its standard dose-titration algorithms based on serum testosterone levels. The Treatment Period will consist of Visits 1 - 12, with cosyntropin stimulation test completed at Visit 9 (Day 169 ±7) and Visit 12 (Day 365 ±7). At each visit during the Treatment Period, subjects will be evaluated for signs and symptoms of adrenal insufficiency, occurrence of adverse events, and changes in concomitant medications. There will be a safety follow-up visit 2 weeks after completion of Visit 12.

研究类型

介入性

注册 (实际的)

116

阶段

  • 第四阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Arizona
      • Tempe、Arizona、美国、85281
        • Alliance for Multispecialty Research
    • California
      • Lincoln、California、美国、95648
        • Clinical Trials Research
      • Long Beach、California、美国、90805
        • Long Beach Research Institute, LLC
      • Tarzana、California、美国、91356
        • Integrated Clinical Research
    • Florida
      • DeLand、Florida、美国、32720
        • Hillcrest Medical Research, LLC
      • Miami、Florida、美国、33135
        • Global Health Clinical Trial Crop
      • Miami、Florida、美国、33176
        • Reserka LLC
      • Ocala、Florida、美国、34470
        • Renstar Medical Research
      • Pompano Beach、Florida、美国、33060
        • Clinical Research Center of Florida
    • Georgia
      • Savannah、Georgia、美国、31406
        • Velocity Clinical Research
    • Maryland
      • Columbia、Maryland、美国、21045
        • Centennial Medical Group
    • Nebraska
      • Omaha、Nebraska、美国、68134
        • Velocity Clinical Research
    • New York
      • Garden City、New York、美国、11530
        • AccuMed Research Associates
      • Rochester、New York、美国、14609
        • Rochester Clinical Research, LLC
    • North Carolina
      • Durham、North Carolina、美国、27701
        • Velocity Clinical Research, Inc.
      • Hickory、North Carolina、美国、28602
        • Catawba Valley Medical Group, Inc.
      • Raleigh、North Carolina、美国、27609
        • Raleigh Medical Group
      • Statesville、North Carolina、美国、28625
        • Piedmont Healthcare, PA
      • Wilmington、North Carolina、美国、28401
        • Wilmington Health, PLLC
    • Texas
      • Austin、Texas、美国、78759
        • Velocity Clinical Research
      • DeSoto、Texas、美国、75115
        • Epic Medical Research LLC
      • Garland、Texas、美国、75041
        • VAST Clinical Research LLC
      • Mesquite、Texas、美国、75149
        • SMS Clinical Research LLC
    • Utah
      • Clinton、Utah、美国、84015
        • Alpine Research Organization, Inc.
      • Salt Lake City、Utah、美国、84124
        • Highland Clinical Research
    • Virginia
      • Norfolk、Virginia、美国、23507
        • Alliance for Multispecialty Research
    • Wisconsin
      • Kenosha、Wisconsin、美国、53144
        • Clinical Investigation Specialists, Inc.

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

男性

描述

Inclusion Criteria:

  1. Subject must be a man 18 to 65 years of age, inclusive, with a previous clinical diagnosis of hypogonadism (signs/symptoms consistent with hypogonadism and a low T level as defined by established criteria at the time of diagnosis); subjects must also have at least 1 T level < 300 ng/dL at either Screen 1 or Screen 2.
  2. Subject must be naïve to androgen replacement therapy or washed out of prior androgen replacement therapies (wash out durations specified in exclusion criterion); that is, be willing to cease current T treatment, or currently not be taking T treatment.
  3. Subject agrees as part of signed informed consent to remain off all forms of T, except for dispensed study drug, throughout the entire study.
  4. Subject must have adequate venous access in the left or right arm to allow collection of blood samples.
  5. Subject must be able and willing to provide written informed consent and comply with the trial protocol and procedures.

Exclusion Criteria:

  • Subject will be excluded if 1 or more of the main exclusion is applicable:

    1. Subject with a history of panhypopituitarism or multiple endocrine deficiencies (whether or not on stable doses of thyroid hormone and adrenal replacement hormones).

    2. Subject with a current or prior history of AI.

    3. Subject is currently receiving corticosteroids.

    4. On the CST at Screen 3, the maximum serum total cortisol at both the 30- and 60-minute timepoint is ≤ 14 mcg/dL or has a baseline CBG outside the reference range.

    5. Subject with a history of a short course (2 weeks or less) of any glucocorticoids within the past 3 months or anabolic steroids other than testosterone within the past 6 months.

    6. Subject with a history of a protracted course of any glucocorticoid therapy (e.g., inhaled nasal steroids, inhaled oral steroids, topical steroids, injectable steroids such as joint injections) or anabolic steroids other than T. Enrolled subjects who take glucocorticoids while on study drug may be discontinued from the study at the discretion of the investigator in consultation with the sponsor.

    7. Subject with a history of anabolic steroid abuse.

    8. Subject with a diagnosis of hypogonadism who has received any topical (e.g., gel or patch), intranasal, or buccal T therapy within the previous 2 weeks, intramuscular T injection of short-acting duration (e.g., T enanthate, T cypionate) within the previous 4 weeks, intramuscular T injection of long-acting duration (e.g., AVEED®) within the previous 20 weeks, T implantable pellets (Testopel®) product within the previous 6 months or any prior use of an oral testosterone product.

    9. Subject has received any drug as part of another research study within 30 days of initial dose administration in this study.

    10. Subject has significant intercurrent disease (e.g., liver, kidney, inflammatory bowel disease, uncontrolled or poorly controlled heart disease, including hypertension, thromboembolism, congestive heart failure, or coronary heart disease, psychiatric illness, including severe depression), which in the opinion of the Investigator, would affect study participation or interpretation of study assessments.

    11. Subject has untreated, severe obstructive sleep apnea.

    12. Subject has clinically significant abnormal laboratory values, including serum transaminases > 2 × upper limits of normal (ULN), serum bilirubin > 1.5 × ULN (except subjects with Gilbert syndrome) and serum creatinine > 1.5 × ULN.

    13. Subject has a HCT value of < 35% or > 50%.

    14. Subject has a history of polycythemia, either idiopathic or associated with TRT treatment.

    15. Subject is diabetic with a glycosylated hemoglobin > 8.5%.

    16. Subject has a body mass index (BMI) ≥ 38 kg/m2.

    17. Subject has had a recent (within 2 years) history of stroke, transient ischemic attack, or acute coronary event.

    18. Subject has a mean (triplicate assessments) systolic blood pressure (sBP) > 140 mm Hg and/or diastolic blood pressure (dBP) > 90 mm Hg at screening (if prescribed antihypertensives, subject should be taking medications on the day of the screening visit with a sip of water).

    19. Subject has had recent (within 2 years) history of angina or stent (coronary or carotid) placement.

    20. Subject does not meet the requirements for concomitant medication as outlined below:

      1. If hypertensive, on a stable dose of antihypertensive medication for < 3 months
      2. If diabetic, on a stable dose of oral medication for < 2 months
      3. If on anticonvulsant therapy, on a stable dose for < 3 months
      4. If on lipid lowering medications, on a stable dose for < 3 months. Subject is expected to remain on a stable dose of lipid-lowering medication(s) throughout the study.
    21. Subject has an abnormal prostate DRE (palpable nodules), elevated PSA (serum PSA > 4.0 ng/mL), I-PSS > 19 points at screening.

    22. Subject has a history of, or current or suspected prostate cancer.

    23. Subject has a history of, or current or suspected breast cancer.

    24. Subject currently using a drug known to affect T levels, T metabolism or levels of T metabolites. These include: 5-alpha-reductase inhibitors (e.g., dutasteride, finasteride), estrogens, long-acting opioid analgesics (e.g., methadone hydrochloride, buprenorphine hydrochloride), human growth hormone (HGH) or over-the-counter supplements purported to "boost" testosterone, sexual function or improve prostate symptoms.

    25. Subject use of dietary supplements such as saw palmetto or phytoestrogens and any dietary supplements that may increase total T, such as androstenedione or dehydroepiandrosterone within the previous 4 weeks.

    26. Subject use of any over-the-counter "adrenal supplements".

    27. Subject is not willing to stop all supplemental biotin 3 days prior to testing at intervals described in this protocol.

    28. Subject currently using Megace, atypical anti-psychotics (e.g., clozapine, aripiorazole, asenapine, lumateperone, olanzapine, paliperidone, aripiprazole, ziprasidone, cariprazine, risperidone, pimavanserin, ioperidone, brexpiprazole, lurasidone, quetiapine) or chronic benzodiazepine use.

    29. Subject has a history of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation within the previous 2 years.

    30. Subject has history of abuse of alcohol or any drug substance within the previous 2 years.

    31. Subject deemed to be a compliance risk or unlikely to keep clinic appointments.

    32. Subject donated blood (≥ 500 mL) within the 12-week period before the initial study dose.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:JATENZO® twice daily

JATENZO capsules will be provided in 3 dosage strengths: 158 mg, 198 mg, 237 mg twice daily

158 mg JATENZO 198 mg JATENZO 237 mg JATENZO

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
CST Test
大体时间:6 months and 12 months

To estimate the proportion of subjects with an abnormal post-stimulation cosyntropin stimulation test (CST) serum total cortisol level after approximately 6 and 12 months of treatment with JATENZO

6 months and 12 months

次要结果测量

结果测量
措施说明
大体时间
Adrenal Insufficiency
大体时间:12 months

To estimate the proportion of subjects who develop primary adrenal insufficiency (AI) as assessed by clinical symptoms of AI and laboratory assessment of cortisol production after approximately 12 months of treatment with JATENZO

12 months

其他结果措施

结果测量
措施说明
大体时间
Hormone changes
大体时间:3 months and 6 months

To estimate the changes from baseline in estrogen (E), follicle stimulating hormone (FSH), and luteinizing hormon (LH) after approximately 3 and 6 months of treatment with JATENZO

3 months and 6 months
Sperm analysis
大体时间:3 months and 6 months

To estimate the changes from baseline in sperm concentration, sperm motility, and total motile sperm count (TMSC) after approximately 3 and 6 months of treatment with JATENZO

3 months and 6 months
Testis volume analysis
大体时间:3 months and 6 months

To estimate the changes from baseline in testicular size after approximately 3 and 6 months of treatment with JATENZO

3 months and 6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月2日

初级完成 (实际的)

2025年11月25日

研究完成 (实际的)

2025年11月25日

研究注册日期

首次提交

2024年4月19日

首先提交符合 QC 标准的

2024年4月23日

首次发布 (实际的)

2024年4月26日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月28日

最后验证

2026年6月1日

更多信息

与本研究相关的术语

其他研究编号

  • TOL-CLAR-20024

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅